Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "SEC"

2673 News Found

Merck unveils $3 billion cost cutting plan
News | July 30, 2025

Merck unveils $3 billion cost cutting plan

The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas


Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business
People | July 29, 2025

Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business

His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors


Biocon Foundation and IISc commemorate World Head & Neck Cancer Day
News | July 29, 2025

Biocon Foundation and IISc commemorate World Head & Neck Cancer Day

This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines


Torrent Pharmaceuticals appoints Aman Mehta as MD
People | July 29, 2025

Torrent Pharmaceuticals appoints Aman Mehta as MD

Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York


Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries
Opinion | July 28, 2025

Rise of Bio-based Chemicals: Hype or Game-Changer?: Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries

The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production


Laurus Labs allotted 531.77 acres of land by the Govt. of Andhra Pradesh
News | July 28, 2025

Laurus Labs allotted 531.77 acres of land by the Govt. of Andhra Pradesh

The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Clinical Trials | July 21, 2025

Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population


AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer
Clinical Trials | July 21, 2025

AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer

Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination


Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer
Drug Approval | July 21, 2025

Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer

European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)